



BIODIEM LTD

ABN 20 096 845 993

Level 4,

100 Albert Rd,

South Melbourne, Victoria, 3205

Australia

Phone: +613 9692 7240

Web: [www.biodiem.com](http://www.biodiem.com)

## Announcement

Melbourne, 7<sup>th</sup> August 2015:

Dear Shareholders,

We are pleased to update you about the progress of our wholly-owned subsidiary, Opal Biosciences Limited ("Opal") and the development of its next generation antimicrobial products.

Last month we concluded the first stage of investment in Opal following approval by BioDiem shareholders. A warm welcome to our new Opal shareholders!

If you missed the first stage of new investment in Opal, the capital raising is still open for sophisticated investors. This opportunity gives a stake in our technology at this pivotal time. See our website for details (<http://www.opalbiosciences.com>).

It is important to note, all BioDiem shareholders will retain a stake in the Opal technology through the shareholding in Opal held by BioDiem. However those BioDiem shareholders deemed "sophisticated investors" are also eligible to purchase more shares.

As you are aware, we recently established Opal to allow outside investment in the project to help fast track the development of our promising BDM-I program (now called Opal Technology). Opal is developing two products: Opal-I, an injectable product, and Opal-T, which can be applied to skin.

We have now commenced the formulation program of Opal-I so it can be used in preclinical studies, the precursors to human studies. We will update you as we progress. Antibiotic-resistant illnesses and superbugs are emerging as one of the biggest health threats of our time, so the need for products such as Opal's cannot be underestimated.

Our goal is to trade sale or partner the technology into the US market within the next 2-3 years. The US has attractive incentives for antimicrobial product development and resources which are either not available or far more suitable than currently available in Australia.

Next week in Singapore I will be meeting local investors to introduce Opal Biosciences and seek further investment. I will also be presenting the Opal technology at Wholesale Investors' Asia-Pacific Emerging Company Expo 2015 – Singapore.

The event will feature Australia's, Singapore's and New Zealand's most innovative emerging growth companies and will be attended by around 500 investors, brokers, fund managers, media and industry participants.

For further details please ring our team on (03) 9692 7240 or email: [info@biodiem.com](mailto:info@biodiem.com), follow us on twitter @biodiem, @opalbiosciences.

I look forward to providing you with news as it happens.

Yours sincerely,



**Julie Phillips**

**Chief Executive Officer**

BioDiem Ltd

Phone + 61 3 9692 7240

Twitter @biodiem

Email [jphillips@biodiem.com](mailto:jphillips@biodiem.com)

- ENDS -

#### **About BioDiem Ltd**

BioDiem is an Australian biopharmaceutical company that is focussed on developing and commercialising vaccines and infectious disease therapies. BioDiem's business model is to generate income from partnerships including with other vaccine and infectious disease treatment companies through existing and new licences to its LAIV vaccine and other technologies. Income comes from licence fees and royalties on sales.

BioDiem's lead technology is the LAIV (Live Attenuated Influenza Virus) vaccine technology used for production of seasonal and pandemic influenza vaccines and is given intranasally. This technology is licensed currently to two commercial partners, in India and China, and is licenced to the World Health Organisation as part of the Global Pandemic Influenza Action Plan to Increase Vaccine Supply. Serum Institute of India's Nasovac-S™ is based on BioDiem's technology and is already marketed in India.

BioDiem's antimicrobial technology, BDM-I, is being developed through its subsidiary, Opal Biosciences Ltd. For additional information, please visit [www.biodiem.com](http://www.biodiem.com).

#### **About Opal Biosciences Ltd**

Opal Biosciences is an Australian biotechnology company and an innovative player in infectious disease treatment. The unmet need for new anti-infectives is due to increasing resistance to existing antibiotics, more widespread and common difficult-to-treat infections, and the paucity of upcoming new treatments. This need has spurred the EU and US to introduce significant financial incentives to encourage development of new anti-infectives. Opal is currently seeking funding to support the next stage of development of our products:

- Opal-I, an injectable product, and
- Opal-T, which can be applied to the skin.

For more information, please visit [www.opalbiosciences.com](http://www.opalbiosciences.com).